Typhoid Fever Vaccines Market By Vaccine Type (Live Attenuated Vaccine, Capsular Polysaccharide Vaccines, Conjugate Vaccine, and Others), by Typhoid Fever Vaccines Type (Oral and Parental), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

  • Published On : Mar 2019 |
  • Pages : 177 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Typhoid Fever Vaccines Market- Insights

Typhoid fever, also simply called as typhoid is a bacterial infection caused by Salmonella typhi, also known as Salmonella enterica serotype Typhi. The typhoid fever is usually caused due to ingestion of contaminated food or water. Typhoid vaccines prevents typhoid fever and provide protection against it. World Health Organization (WHO) has recommended three typhoid vaccines for use, which include live attenuated vaccine, capsular polysaccharide vaccines, and conjugate vaccine

Increasing government initiatives promoting and advancing development of innovative products

Organizations such as World Health Organization (WHO), Gavi, Bill & Melinda Gates Foundation, and others are highly active in creating awareness regarding typhoid and driving immunization efforts against such diseases

For instance, in October 2017, WHO recommended introduction of typhoid vaccine for children over six months in endemic countries. It also recommended catch-up vaccination whenever possible, prioritizing children and adolescents up to 15 years of age.

Moreover, World Health Organization (WHO), pre-qualified a typhoid conjugate vaccine (TCV) Typbar TCV, manufactured by Bharat Biotech in December 2017. WHO pre-qualification enables the procurement and supply of this vaccine to UNICEF, the Pan-American Health Organization (PAHO), and GAVI (a vaccine alliance) supported countries. Such frequent initiatives taken by various organizations is expected to support the market growth over the forecast period.

High prevalence of typhoid in various emerging economies is expected to rise the demand for typhoid vaccines in near future and fuel global typhoid fever vaccines market growth. For instance, according to the International Health Metrics and Evaluation (IHME) estimates in 2016, around 12 million cases of typhoid fever were reported resulting in around 130,000 deaths globally   

The global typhoid fever vaccines market size was valued at US$ 225.0 Mn in 2018, and is expected to witness a CAGR of 11.9% during the forecast period (2018 – 2026).

Figure 1. Global Typhoid Fever Vaccines Market Share (%), By Vaccine Type, 2018-2016

Typhoid Fever Vaccines  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2018)

Asia Pacific is expected to hold dominant position in the market owing to high prevalence of typhoid fever in the region

Asia Pacific is expected to be most lucrative region for typhoid fever vaccines market growth, owing to countries such as India, Pakistan, and Bangladesh are endemic to typhoid wherein the demand for typhoid vaccine is every high. For instance, according to the data published by Med India around 18, 45,997 cases of typhoid were found in India in 2015. Furthermore, presence of key typhoid vaccine manufacturers in region and development and launch of novel vaccines by them is also expected to drastically drive market growth over the forecast period

For instance, Bharat Biotech and Bio-Med Private Limited are two India-based typhoid vaccine manufacturer in Asia Pacific. In 2013, Bharat Biotech launched its new clinically proven conjugate Typhoid vaccine namely Typbar-TCV, which offers long-term protection and can be given to children as young as six months.

Figure 2. Global Typhoid Fever Vaccines Market Share (%) Analysis, By Region, 2026

Typhoid Fever Vaccines | Coherent Market Insights

Source: Coherent Market Insights Analysis (2018)

Reimbursement Scenario

Vaccination/Immunizations are generally not covered under medicare, unless they are directly related to the treatment of an injury or direct exposure to a disease or condition, such as anti-rabies treatment or tetanus antitoxin or booster vaccine.

In absence of such condition where an injury or direct exposure has happened, vaccination (preventive immunization) against diseases such as smallpox, typhoid and polio, are not covered.

In cases where a vaccination or inoculation is excluded from coverage, the entire charge will be denied (such as office visits, which are primarily for the purpose of administering a non-covered injection).

Market Opportunity

Currently, there is only one typhoid conjugate vaccine that has been prequalified by WHO (Typbar TCV) to treat young children below two years of age. Typhoid conjugate vaccine (TCV) is more effective at preventing the disease than other available vaccines. It is long lasting, provides protection for at least five years and possibly longer, as compared to just two years for earlier typhoid vaccines.

Childhood vaccination schedules are still devoid of a typhoid vaccine. However, with introduction of Typbar TCV, the scenario is expected to change, as these vaccines would be included in the childhood vaccination schedules giving immunity against typhoid to infants early.

Typhoid conjugate vaccine increased the immunization age range to include children under age two, a particularly vulnerable and typhoid susceptible part of the population. Manufacturers can develop novel typhoid vaccine with better and longer clinical protection, broader target age range (including children <2 years of age), cost effectiveness, and other factors, which are not met by currently available vaccines

Key players operating in the typhoid fever vaccines market include GlaxoSmithKline Plc., Sanofi SA, Bharat Biotech, Bio-Med Pvt. Ltd., PT Bio Farma, PaxVax, Inc. Shanghai Institute of Biological Products Co., Ltd., and Prokarium

Typhoid fever is a bacterial infection caused by Salmonella typhi, which causes symptoms such as prolonged fever, headache, nausea, loss of appetite, and constipation or sometimes diarrhea. Typhoid fever is majorly caused in area with poor sanitation and lack of clean drinking water. Typhoid fever vaccines are the biological formulation, which provide immunity and protects an individual against typhoid fever

Currently there are three typhoid vaccines recommended World Health organization (WHO) for use which include:

  • Injectable typhoid conjugate vaccine (TCV), consisting of Vi polysaccharide antigen linked to tetanus toxoid protein licensed for children from 6 months of age and adults up to 45 years of age;
  • Injectable unconjugated polysaccharide vaccine based on the purified Vi antigen (known as Vi-PS vaccine) for persons aged two years and above; and
  • Oral live attenuated Ty21a vaccine in capsule formulation for those over six years of age.

Market Dynamics

High prevalence of typhoid fever in region such as Asia Pacific and Africa is expected to drastically rise demand for its vaccines and support global typhoid fever vaccines market growth over the forecast period.

For instance, according to the data published by World Health Organization (WHO) in September 2018, globally between 11 and 21 million cases of typhoid were found, which caused around 128 000 to 161 000 typhoid-related deaths occur annually.

According to the data published by National Center for Biotechnology Information (NCBI) in 2018, incidence of typhoid fever in Africa was estimated to be 10–100 cases per 100,000

Increasing initiatives by government and various other organizations to increase awareness about typhoid vaccine and rising access of new vaccines is expected to support typhoid fever vaccines market growth during forecast period.

For instance, in February 2019, Gavi, the Vaccine Alliance in partnership with WHO, CDC and Zimbabwe’s Ministry of Health launched a campaign to tackle typhoid outbreak in Zimbabwe. The campaign aims to vaccinate 325,000 people in nine suburbs of Zimbabwe’s capital with new typhoid conjugate vaccine (TCV).

Key features of the study:

  • This report provides in-depth analysis of Typhoid fever vaccines market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global Typhoid fever vaccines market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
  • Key companies covered as a part of this study include GlaxoSmithKline Plc., Sanofi SA, Bharat Biotech, Bio-Med Pvt. Ltd., PT Bio Farma, PaxVax, Inc. Shanghai Institute of Biological Products Co., Ltd., and Prokarium.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global Typhoid fever vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the Typhoid fever vaccines market

Detailed Segmentation:

  • Global Typhoid Fever Vaccines Market, By Vaccine Type :
    • Live Attenuated Vaccine
    • Capsular Polysaccharide Vaccines
    • Conjugate Vaccine
    • Others
  • Global Typhoid Fever Vaccines Market, By Route of Administration:
    • Oral
    • Parenteral
  • Global Typhoid Fever Vaccines Market, By Geography:
    • North America
      • By Vaccine Type :
        • Live Attenuated Vaccine
        • Capsular Polysaccharide Vaccines
        • Conjugate Vaccine
        • Others
      • By Route of Administration:
        • Oral
        • Parenteral
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Vaccine Type :
        • Live Attenuated Vaccine
        • Capsular Polysaccharide Vaccines
        • Conjugate Vaccine
        • Others
      • By Route of Administration:
        • Oral
        • Parenteral
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Vaccine Type :
        • Live Attenuated Vaccine
        • Capsular Polysaccharide Vaccines
        • Conjugate Vaccine
        • Others
      • By Route of Administration:
        • Oral
        • Parenteral
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Vaccine Type :
        • Live Attenuated Vaccine
        • Capsular Polysaccharide Vaccines
        • Conjugate Vaccine
        • Others
      • By Route of Administration:
        • Oral
        • Parenteral
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • By Vaccine Type :
        • Live Attenuated Vaccine
        • Capsular Polysaccharide Vaccines
        • Conjugate Vaccine
        • Others
      • By Route of Administration:
        • Oral
        • Parenteral
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Vaccine Type :
        • Live Attenuated Vaccine
        • Capsular Polysaccharide Vaccines
        • Conjugate Vaccine
        • Others
      • By Route of Administration:
        • Oral
        • Parenteral
      • By Country:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • GlaxoSmithKline Plc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Sanofi SA
    • Bharat Biotech
    • Bio-Med Pvt. Ltd.
    • PT Bio Farma
    • PaxVax, Inc.
    • Shanghai Institute of Biological Products Co., Ltd.
    • Prokarium

 “*” marked represents similar segmentation in other categories in the respective section.

 

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Vaccine Type
      • Market Snippet, By Route of Administration
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Novel Product Launch/Approval
    • PEST Analysis
    • Awareness Strategy
    • Reimbursement Scenario
    • Typhoid Fever Vaccines Shortage
    • Clinical Trial Analysis
    • Countries with High Number of Incidents of Snake Bites
    • Market Entry Challenges
  4. Global Typhoid Fever Vaccines Market, By Vaccine Type, 2016 – 2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Live Attenuated Vaccine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Capsular Polysaccharide Vaccines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Conjugate Vaccine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  5. Global Typhoid Fever Vaccines Market, By Route of Administration, 2016 – 2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017–2026
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
    • Parental
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
  6. Global Typhoid Fever Vaccines Market, By Region, 2016 – 2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Vaccine Type, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Vaccine Type, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Vaccine Type, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of APAC
    • Latin America
      • Market Size and Forecast, By Vaccine Type, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Vaccine Type, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • Central Africa
        • South Africa
        • North Africa
    • Middle East
      • Market Size and Forecast, By Vaccine Type, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016 – 2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
  7. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • GlaxoSmithKline Plc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sanofi SA
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bharat Biotech
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bio-Med Pvt. Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • PT Bio Farma
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • PaxVax, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Shanghai Institute of Biological Products Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Prokarium
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 26 market data tables and 325 figures on “Typhoid Fever Vaccines Market - Global forecast to 2026”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.